SCHEDULE: Evogene Ltd.: Activist Investors Demand Board Shakeup

Major shareholders have formally demanded a special general meeting to replace most of Evogene's board of directors, citing financial underperformance and a need for strategic refreshment.

Summary

• L.I.A. Pure Capital Ltd. and Invest Pro Shukai Hon Ltd., collectively holding approximately 16.7% of Evogene Ltd.'s voting rights, have demanded a special general meeting of shareholders.
• The demand, dated July 10, 2026, seeks to remove most of the current board members (excluding Ofer Haviv) and elect new nominees with expertise in finance, governance, and science.
• The activist investors cite a significant decline in revenue (86% in Q1 2026), operating losses, and continued reliance on external capital raises as reasons for the proposed board changes.
• They propose specific nominees: Itay Maroz (finance/business), Oz Adler (finance/governance), Dr. Adi Zuloff-Shani (scientific expertise), and Shahar Zadok (PR/IR).
• The shareholders support the continued service of Ofer Haviv as CEO.
• The demand also includes proposals for approving compensation, exemption, indemnification, and insurance arrangements for the new nominees.
• The special meeting must be called by July 31, 2026, and held by September 4, 2026.
• The activist investors have also requested interim measures to preserve the status quo, preventing material transactions or dilutive actions until the new board is in place, though they are open to providing loans or investments on market terms if necessary.
• L.I.A. Pure Capital Ltd. beneficially owns approximately 12.61% of Evogene's shares, and Invest Pro Shukai Hon Ltd. beneficially owns approximately 4.13%.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to the significant financial underperformance cited by activist investors and the demand for a board overhaul, indicating substantial dissatisfaction with current management and strategy.

Positives

• The activist investors express support for the continued service of Ofer Haviv as President and CEO, recognizing his familiarity with the company's operations and strategy.
• The proposed director nominees bring a diverse and complementary set of skills, including financial, governance, scientific, and investor relations expertise, which could strengthen board oversight.
• The activist investors are willing to consider providing loans or making investments on market terms if the company requires additional funds before the special meeting.

Negatives

• Evogene's financial performance has deteriorated, with revenues declining approximately 86% in the first quarter of 2026 compared to the prior year, totaling only approximately US$0.3 million.
• The company recorded an operating loss of approximately US$3.2 million and a net loss of approximately US$5.9 million in Q1 2026.
• The company's operations continue to rely significantly on external capital raises rather than organic business growth, leading to repeated dilution of shareholder equity.
• The current board composition is deemed insufficient by the activist investors to translate technological capabilities into sustainable commercial success and shareholder value.

Risks

• The demand for a special general meeting and potential board changes could lead to corporate governance instability and distract management from operational priorities.
• Failure to convene the special meeting by the specified deadlines could result in legal action by the shareholders, including petitions to the court to order the meeting and potential reimbursement of costs.
• The activist investors have reserved their rights and may hold directors personally liable for damages resulting from actions that breach fiduciary duties.
• The interim period's demand to preserve the status quo could restrict the company's ability to pursue necessary business opportunities or financing if not carefully managed.

Future Outlook

The future outlook is contingent on the outcome of the demand for a special general meeting. The activist investors aim to refresh the board to improve strategic direction, capital allocation, and execution, with the goal of enhancing shareholder value and achieving sustainable commercial success. The company's ability to generate internal cash flow and reduce reliance on external capital raises will be critical.

Management Comments

• The Shareholders support Mr. Ofer Haviv's continued service as President and Chief Executive Officer of the Company. Mr. Haviv has considerable familiarity with the Companys operations, technology and strategic direction, and we believe his experience and qualifications position him well to continue leading the Company during this period. The proposed changes to the Boards composition are intended to complement his leadership.
• We believe that the current Board of Directors of the Company (the Board) has not achieved the level of value creation that shareholders were entitled to expect.
• In our view, these figures demonstrate that the current strategy has yet to translate into sustainable commercial success or meaningful value creation for shareholders.
• The central responsibility of a board of directors is not limited to overseeing innovation - it also encompasses ensuring that innovation is translated into measurable commercial success and sustained returns for shareholders.
• In light of the disappointing financial performance, persistent losses and continued reliance on external funding sources, we believe the time has come for a refreshment of the Board through the appointment of directors with complementary experience, renewed strategic thinking and a proven ability to execute - who will act to realize the Companys potential and maximize value for the benefit of all shareholders.

Industry Context

StockSavvy.ai notes that shareholder activism is a recurring theme in the biotechnology and development-stage sectors, where companies often require significant capital and face long development cycles. Demands for board changes are typically triggered by perceived underperformance, strategic missteps, or a lack of alignment between management and shareholder interests, especially when financial results are weak and dilution is significant.

Comparison to Industry Standards

• The reported Q1 2026 revenue decline of 86% and net loss of US$5.9 million are significantly worse than typical performance for established biotechnology companies. While development-stage companies often experience losses, such a steep revenue drop suggests substantial operational challenges.
• The reliance on external capital raises, including warrant exercises, is common for companies in early to mid-stage development. However, the activist investors' concern about repeated dilution without commensurate operational progress highlights a potential deviation from best practices in capital allocation, which typically aim for more sustainable growth drivers.
• The proposed director nominees' profiles (finance, governance, scientific, PR/IR) align with the diverse expertise sought for boards of directors in the life sciences industry, aiming to balance scientific understanding with financial acumen and strategic oversight.

Management Changes

Corporate Governance

Legal Proceedings

• The activist investors reserve the right to petition the court to order the convening of the Special Meeting if the Board fails to do so timely.
• The activist investors reserve the right to hold directors personally liable for damages resulting from breaches of fiduciary duties.

Stakeholder Impact

• Shareholders: Directly impacted by the demand for board changes, with potential for improved governance and value creation if successful, or instability if not.
• Employees: May experience uncertainty regarding future strategy and leadership, but could benefit from improved company performance.
• Management: Current board members targeted for removal face potential job loss. Ofer Haviv's position as CEO is supported, but his role may be influenced by a new board.
• Creditors: Potential impact on the company's financial stability and ability to service debt depends on the outcome of the activist campaign and future performance.

Next Steps

• The Board of Directors must call a special general meeting by July 31, 2026.
• The special general meeting must be held by September 4, 2026.
• Shareholders will vote on proposals to remove current directors (excluding Ofer Haviv) and elect new director nominees.
• Compensation, exemption, indemnification, and insurance arrangements for the new nominees will be subject to approval.
• The Reporting Persons intend to engage in discussions with the Issuer's board, management, and shareholders.
• The Reporting Persons may take further actions to seek shareholder support for their proposals.
• The Reporting Persons intend to memorialize their oral voting agreement in a written voting agreement.

Key Dates

Recommendation

The filing indicates significant shareholder dissatisfaction and a demand for board changes due to poor financial performance. While the activist investors' proposed nominees offer potential for improved governance and strategy, the outcome of the special meeting is uncertain. The company's financial health remains a concern. Therefore, a 'hold' recommendation is appropriate pending the resolution of the board challenge and a clearer view of the company's future direction and performance.

Keywords

Evogene Ltd., Schedule 13D, Shareholder Activism, Board of Directors, Special General Meeting, Corporate Governance, Activist Investors, L.I.A. Pure Capital Ltd., Invest Pro Shukai Hon Ltd., Kfir Silberman, Ron Yair Peled, Financial Performance, Director Nominees